ClinicalTrials.gg
RecruitingNCT07632872Updated Jun 8, 2026

Desloratadine as Adjunct Therapy for Rheumatoid Arthritis

A Phase 2 interventional study of Desloratadine 5 mg and Placebo in Rheumatoid Arthritis (RA) and Rheumatoid Arthritis, sponsored by Horus University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Horus University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Arthritis, Rheumatoid with a site in Egypt — 35 open to participants now, 36 under way, 9 of them phase 3. Arthritis, Rheumatoid · Egypt.

Planned enrollment
30th of 56
60 · median 68
Started
2026
with 13 others
Phase 2
12 of 88
8 open now
Primary completion
2026-11
later than 23 of 35 live
Registered
80th of 88
by date
Lead sponsor
3 of 88
Horus University

Among the 88 studies in Arthritis, Rheumatoid with a site in Egypt, this one is the 30th largest by planned enrollment of the 56 interventional ones that give a count, is one of 14 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 23 of the 35 other live ones, and was the 80th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

35 of the 88 studies in Arthritis, Rheumatoid with a site in Egypt are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Arthritis, Rheumatoid with a site in Egypt, or all of them as a file.
02

Study summary

Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease.

The purpose of this study is to evaluate the effectiveness and safety of adding desloratadine to standard therapy in patients with active rheumatoid arthritis. Participants will receive either desloratadine or placebo in addition to their usual treatment.

The study will assess changes in disease activity and inflammatory markers over a follow-up period of approximately 12 weeks. The results of this study may help determine whether desloratadine could be a useful add-on treatment option for patients with rheumatoid arthritis.

Read the detailed description

rheumatoid arthritis. desloratadine has been shown to exhibit additional anti-inflammatory properties beyond its antihistaminic effect.

This randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of desloratadine as add-on therapy to standard DMARD treatment in patients with rheumatoid arthritis. Eligible participants will be randomized into two parallel groups to receive either desloratadine, or placebo for a duration of three months.

Clinical assessments will include evaluation of disease activity scores, inflammatory biomarkers, and patient-reported outcomes. Safety and tolerability will be monitored throughout the study period. The findings of this study may provide evidence for novel adjunctive therapeutic strategies in the management of rheumatoid arthritis.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
  • Rheumatoid Arthritis

Keywords

  • Desloratadine
  • Rheumatoid arthritis
  • Add-on therapy
  • Inflammation
  • Randomized controlled trial
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with active rheumatoid arthritis according to the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria.
  • Disease Activity Score in 28 joints (DAS28) greater than 2.6.
  • Age between 18 and 60 years.
  • Male and female patients.
  • Patients receiving methotrexate in addition to standard conventional therapy.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Patients with renal or hepatic disease.
  • Known to the study medications.
  • Current use of antioxidant supplements.
  • History of psychiatric disorders.
  • Use of oral prednisolone at a dose greater than 15 mg per day.
  • Current treatment with biological disease modifying antirheumatic drugs.
  • Pregnant or breastfeeding patients.
  • History of cardiac arrhythmias or prolonged .
  • Use of medications known to prolong the QT interval.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Desloratadine Group

    Participants will receive desloratadine 5mg in addition to standard disease modifying antirheumatic drug therapy.

    Drug: Desloratadine 5 mg

  • Experimental
    Placebo Group

    Participants will receive placebo in addition to standard disease modifying antirheumatic drug therapy.

    Drug: Placebo

Interventions

  • DrugDesloratadineStudies of DesloratadineDesloratadine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Desloratadine administered orally as add on therapy to standard disease modifying antirheumatic drugs.

    Also known as: Desloratadine

  • DrugPlacebo

    Matching placebo administered orally as add on therapy to standard disease modifying antirheumatic drugs.

06

What researchers measure

Primary outcomes

  1. Change in Disease Activity Score (DAS28)

    Change in disease activity assessed by the Disease Activity Score in 28 joints (DAS28), calculated using tender and swollen joint counts, patient global assessment, and inflammatory markers. DAS28 values are interpreted as follows: remission is defined as a score less than 2.6, low disease activity as 2.6 to 3.2, moderate disease activity as greater than 3.2 to 5.1, and high disease activity as greater than 5.1. The outcome compares DAS28 values at baseline and after 12 weeks of treatment with desloratadine or placebo.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

Of 42 non-industry phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's planned 6 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 8, 2026
StartActual
May 23, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Jan 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07632872
Lead sponsor
Horus University
Responsible party
Amira Fawzy Mohamed Mashaly (Principal Investigator, Horus University) — Principal investigator
First posted
Jun 8, 2026
Start date
May 23, 2026
Primary completion
Nov 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Amira Mashaly
Contact
amashaly@horus.edu.eg
01028275001
Amira Mashaly
principal investigator · Horus University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desloratadine

Start the discussion